These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 16881431

  • 41. Fentanyl pharmacokinetics in patients undergoing renal transplantation.
    Koehntop DE, Rodman JH.
    Pharmacotherapy; 1997; 17(4):746-52. PubMed ID: 9250552
    [Abstract] [Full Text] [Related]

  • 42. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.
    Zelenitsky SA, Ariano RE, McCrae ML, Vercaigne LM.
    Clin Infect Dis; 2012 Aug; 55(4):527-33. PubMed ID: 22573855
    [Abstract] [Full Text] [Related]

  • 43. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.
    Nakayama H, Echizen H, Tanaka M, Sato M, Orii T.
    Ther Drug Monit; 2008 Feb; 30(1):103-7. PubMed ID: 18223471
    [Abstract] [Full Text] [Related]

  • 44. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
    Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E.
    Anesthesiology; 2009 Aug; 111(2):356-65. PubMed ID: 19602966
    [Abstract] [Full Text] [Related]

  • 45. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
    Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM.
    J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
    [Abstract] [Full Text] [Related]

  • 46. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL, Stalker D, Keirns J.
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [Abstract] [Full Text] [Related]

  • 47. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
    Dailly E, Le Floch R, Deslandes G, Pannier M, Jolliet P.
    Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
    [Abstract] [Full Text] [Related]

  • 48. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease.
    Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ.
    Am J Kidney Dis; 1995 Sep; 26(3):469-74. PubMed ID: 7645555
    [Abstract] [Full Text] [Related]

  • 49. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen.
    Kamel Mohamed OH, Wahba IM, Watnick S, Earle SB, Bennett WM, Ayres JW, Munar MY.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):694-9. PubMed ID: 17699484
    [Abstract] [Full Text] [Related]

  • 50. An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis.
    Maynor LM, Carl DE, Matzke GR, Gehr TW, Farthing C, Farthing D, Brophy DF.
    Pharmacotherapy; 2008 Aug; 28(8):977-83. PubMed ID: 18657014
    [Abstract] [Full Text] [Related]

  • 51. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P, Ortiz M, Ortega O, Rodríguez I, Seijas V, Carreño A, Oliet A, Vigil A.
    Nefrologia; 2007 Aug; 27(1):46-52. PubMed ID: 17402879
    [Abstract] [Full Text] [Related]

  • 52. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
    Teigen MM, Duffull S, Dang L, Johnson DW.
    J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791
    [Abstract] [Full Text] [Related]

  • 53. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M, Kuroda K.
    Clin Ther; 1981 Nov; 4 Suppl A():124-32. PubMed ID: 6275994
    [Abstract] [Full Text] [Related]

  • 54. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.
    De Waele JJ, Danneels I, Depuydt P, Decruyenaere J, Bourgeois M, Hoste E.
    Int J Antimicrob Agents; 2013 May; 41(5):434-8. PubMed ID: 23410793
    [Abstract] [Full Text] [Related]

  • 55. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H.
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
    Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM.
    Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
    [Abstract] [Full Text] [Related]

  • 58. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
    Jeurissen A, Sluyts I, Rutsaert R.
    Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Vancomycin dosing in patients on intermittent hemodialysis.
    Vandecasteele SJ, De Vriese AS.
    Semin Dial; 2011 Jan; 24(1):50-5. PubMed ID: 21338394
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.